AbbVie Inc (ABBV)

Add to Watchlists
Create an Alert
Quickflows
78.00 +2.27  +3.00% NYSE Apr 7, 09:35 Delayed 2m USD
View Full Chart
Price Chart
View All Key Stats

Key Stats

View All ABBV News

News

View All Events

Events

Date Type Description
07/24/2020 09:00 EDT Misc AbbVie Inc Second Quarter Earnings Conference Call in 2020
07/24/2020 Earnings AbbVie Inc Second Quarter Earnings in 2020 Release
05/08/2020 09:00 CDT Misc AbbVie Inc Annual General Meeting for 2019
05/01/2020 08:00 CDT Misc AbbVie Inc First Quarter Earnings Conference Call for 2020
05/01/2020 Earnings AbbVie Inc First Quarter Earnings Result for 2020
04/14/2020 Dividends Amount: 1.18, Declared Date: Feb 20 2020, Pay Date: May 15 2020
02/21/2020 Misc AbbVie Inc Annual Report for 2019
02/07/2020 08:00 CST Misc AbbVie Inc Fourth Quarter Earnings Conference Call for 2019
02/07/2020 Earnings AbbVie Inc Fourth Quarter Earnings in 2019 Release
01/14/2020 Dividends Amount: 1.18, Declared Date: Nov 01 2019, Pay Date: Feb 14 2020
View All Performance Charts

Total Returns Comparison

Fundamentals

Income Statement View Statement

Revenue (TTM) 33.27B
Total Expenses (TTM) 19.90B
Net Income (TTM) 7.882B

Balance Sheet View Statement

Total Assets (Quarterly) 89.12B
Total Liabilities (Quarterly) 97.29B
Shareholders Equity (Quarterly) -8.172B

Cash Flow Statement View Statement

Cash from Operations (TTM) 13.32B
Cash from Investing (TTM) 596.00M
Cash from Financing (TTM) 18.71B

Ratings & Reports

Advertisement
Edit

Profile

  • URL: http://www.abbvieinvestor.com
  • Investor Relations URL: http://www.abbvieinvestor.com/phoenix.zhtml?c=251551&p=irol-IRHome
  • HQ State/Province: Illinois
  • Sector: Healthcare
  • Industry: Drug Manufacturers - General
  • Equity Style: Large Cap/Blend
  • Next Earnings Release: May. 01, 2020
  • Last Earnings Release: Feb. 07, 2020
  • Next Ex-Dividend Date: Apr. 14, 2020
  • Last Ex-Dividend Date: Jan. 14, 2020
  • Description: AbbVie is a drug company with a strong exposure to immunology and oncology. The company's top drug, Humira, represents over half of the company's current profits. The company was spun off from Abbott in early 2013. The recent announced acquisition of Allergan will add several new drugs in aesthetics and women's health.

Analyst Coverage

Consensus Recommendations
Buy Recommendations Upgrade
Outperform Recommendations Upgrade
Hold Recommendations Upgrade
Underperform Recommendations Upgrade
Sell Recommendations Upgrade
Consensus Recommendation Upgrade
Consensus Rating Upgrade
Target Price
Price 78.00
Price Target Upgrade
Price Target Upside (Daily) Upgrade

Top Fund Holders

Symbol Name Weighting
XLV Health Care Select Sector SPDR® ETF 3.36%
VHT Vanguard Health Care ETF 3.11%
SDY SPDR® S&P Dividend ETF 2.41%
RCEEX American Funds Capital Income Bldr R2E 2.33%
RIBEX American Funds Invmt Co of Amer R2E 2.06%
RMEBX American Funds American Mutual R2E 1.63%
VYM Vanguard High Dividend Yield ETF 1.34%
VTV Vanguard Value ETF 0.99%
IWF iShares Russell 1000 Growth ETF 0.87%
RWIEX American Funds Capital World Gr&Inc R4 0.81%

Comparables

Edit
AMGN Amgen Inc
BIIB Biogen Inc
GILD Gilead Sciences Inc
JNJ Johnson & Johnson
LLY Eli Lilly and Co

Other Resources

Advertisement

{{root.upsell.info.feature_headline}}.

{{root.upsell.info.feature_description}}

Please note that this feature is only available as an add-on to YCharts subscriptions.

Please note that this feature requires full activation of your account and is not permitted during the free trial period.

Start My Free Trial {{root.upsell.info.call_to_action}} No credit card required.

Already a subscriber? Sign in.